Clinical Trials Directory

Trials / Completed

CompletedNCT05071781

Effect of CRH on Duodenal Markers and Gastric Sensorimotor Function

The Effect of Corticotropin Release Hormone on Duodenal Markers and Gastric Sensorimotor Function in Healthy Volunteers

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

In the present study, during Part 1, after a baseline gastroduodenoscopy, the investigators will perform a gastroduodenoscopy twice, to take duodenal biopsies before and 2 hours after administration of CRH/placebo. The investigators will measure mucosal integrity and markers of immune activation as outlined in Parts A and B, and will use transmission electron microscopy to evaluate mast cell and eosinophil degranulation. After an interval period of at least 1 week, CRH or placebo will be administrated again in a crossover fashion. As a complementary study, the investigators will also test the effect of ex vivo mast cell blockade by lodoxamide to evaluate whether mast cells are involved in the hypothesized effect of CRH on duodenal permeability. In a second part of this study, Part 2, the investigators will perform a gastric barostat, to measure the gastric accommodation and sensitivity to distension, and a carbon-13-octanoic acid breath test to measure the gastric emptying time after administration of CRH/placebo. Healthy volunteers will have the option to choose to which part of the study (part 1 or 2) they wish to participate. They can also choose to cooperate to both study parts if preferred.

Conditions

Interventions

TypeNameDescription
DRUGCorticotropin-release hormoneintravenous CRH (100 µg)
DRUGCorticotropin-release hormonea bolus dose (CRH 100 µg or placebo) will be administered, followed by a continuous infusion (CRH 1 µg/kg/h or placebo)

Timeline

Start date
2021-05-21
Primary completion
2022-12-19
Completion
2022-12-19
First posted
2021-10-08
Last updated
2024-07-03

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT05071781. Inclusion in this directory is not an endorsement.